Search

Your search keyword '"Cheng, Linfang"' showing total 211 results

Search Constraints

Start Over You searched for: Author "Cheng, Linfang" Remove constraint Author: "Cheng, Linfang"
211 results on '"Cheng, Linfang"'

Search Results

4. Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection

23. Novel reassortant influenza A(H5N8) viruses in domestic ducks, eastern China

27. Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19

28. Dynamic Characteristic Analysis of Antibodies in Patients With COVID-19: A 13-Month Study

30. Proteomic Analysis Identifies Prolonged Disturbances in Pathways Related to Cholesterol Metabolism and Myocardium Function in the COVID-19 Recovery Stage

31. sj-pdf-1-jvd-10.1177_10406387211027538 – Supplemental material for Development of an antigen-ELISA and a colloidal gold–based immunochromatographic strip based on monoclonal antibodies for detection of avian influenza A(H5) viruses

33. Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection

35. Molecular Architecture of the SARS-CoV-2 Virus

36. Patient-derived mutations impact pathogenicity of SARS-CoV-2

37. WITHDRAWN: Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for the COVID-19 outbreak

38. Virus strain of a mild COVID-19 patient in Hangzhou represents a new trend in SARS-CoV-2 evolution related to Furin cleavage site

39. Patient-Derived Mutations Impact Pathogenicity of SARS-CoV-2

40. Virus strain from a mild COVID-19 patient in Hangzhou represents a new trend in SARS-CoV-2 evolution potentially related to Furin cleavage site

41. Molecular Architecture of the SARS-CoV-2 Virus

43. Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19.

46. Longevity of protective immune responses induced by a split influenza A (H7N9) vaccine mixed with MF59 adjuvant in BALB/c mice

50. Preclinical evaluation of the safety and pathogenicity of a live attenuated recombinant influenza A/H7N9 seed strain and corresponding MF59-adjuvanted split vaccine

Catalog

Books, media, physical & digital resources